Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression

NCT ID: NCT00163241

Last Updated: 2021-03-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 666 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-06-30
• Study Completion Date: 2006-01-31

Brief Summary

Objectives of the study:

Primary: Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered once daily (QD) for 24 months in slowing disease progression as assessed radiographically in subjects with osteoarthritis (OA) of the hipSecondary:Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered QD for 24 months in treating disease signs and symptoms in subjects with OA of the hip.Evaluate the ability of a continuous 24-month intake of celecoxib 200 mg QD versus placebo to reduce number of subjects eligible for hip replacement according to the investigator.Evaluate the tolerability and safety of a continuous 24-month intake of celecoxib 200 mg QD versus placebo in subjects with OA of the hip.

Detailed Description

The study was terminated on 19 January 2006, prematurely, as a result of low enrollment Safety concerns did not lead to the decision to terminate this study.

Conditions

Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Interventions

celecoxib

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subject is 50 years of age or older.
• If the subject is a female and of childbearing potential, or less than 2 years post-menopausal, she must have been using adequate contraception during her last menses and will use adequate contraception during the study, is not lactating, and has had a negative urine pregnancy test within 24 hours prior to receiving the first dose of study medication. Women less than two years post-menopausal are considered of childbearing potential for the purposes of this study.
• The subject is diagnosed as having OA of the hip as defined by the American College of Rheumatology (ACR) criteria (see Appendix B)
• The subject has symptomatic OA, as defined by the presence of daily hip pain for at least 1 month (not necessarily continuously) during the 2 months prior to screening visit.
• The subject has hip pain of > or equal to 3 and < or equal to 9 on a 10-point Visual Numerical Scale (VNS) in the index hip.
• Subjects with OA of the knee associated with OA of the hip will be included provided knee OA pain intensity is inferior to hip's one and no knee surgery is expected during the study.
• Subjects are functional class I, II or III according to the Steinbrocker criteria (see Appendix C).
• The subject is eligible for pharmacologic treatment to control arthritis symptoms.
• The subject has provided written informed consent before undergoing any study procedures.

Exclusion Criteria

• Bilateral hip OA with contralateral hip more severe symptomatically or radiologically than the index hip.
• The subject has evidence of secondary hip OA.
• Septic arthritis
• Systemic or local inflammatory joint disease (e.g. psoriatic arthritis, spondylarthropathy, systemic lupus erythematosus, etc.)
• Gout
• Recurrent episode of pseudogout
• Paget's disease
• Articular fracture
• Ochronosis
• Acromegaly
• Haemochromatosis
• Wilson's disease
• Primary osteochondromatosis
• Osteonecrosis
• Slipped Capital Femoral Epiphysis (SCFE)
• The subject has a concomitant inflammatory rheumatic condition, which may interfere with the assessment of OA, or acute joint trauma at the index hip.
• The subject has received oral, intramuscular, intravenous, or soft tissue injection of corticosteroids within 4 weeks prior to the screening visit.
• The subject has received an intra-articular injection of corticosteroids or hyaluronic acid in the index hip within 12 weeks prior to the screening visit.
• The subject has received diacerein, chondroitin sulfate, glucosamine sulfate, doxycycline or avocado/soybean unsaponifiables within 12 weeks prior to the screening visit.
• Arthroscopy or a corrective surgery of the index hip has been performed.
• Arthroscopy or a corrective surgery of the contralateral hip has been performed within the 6 months prior to the screening visit .
• Total replacement of the contralateral hip joint was performed within 6 months prior to the screening visit.
• The subject is felt to require hip arthroplasty by the investigator at screening visit.
• The subject has an active malignancy of any type. Subjects who have a history of basal cell carcinoma that has been successfully treated are acceptable. Subjects with a history of other malignancies that have been successfully treated and who have no evidence of recurrence for at least 5 years before study are also acceptable.
• The subject has been diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to the screening visit.
• The subject has a history of recurrent ulceration or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder, a significant coagulation defect, or any other condition, which in the investigator's opinion might preclude use of NSAIDs.
• The subject has a history of intolerance to paracetamol, opioids and tramadol such that it is felt that an adequate non-anti-inflammatory rescue analgesic regimen cannot be safely prescribed, or has a history of alcohol or substance abuse.
• The subject has known hypersensitivity to celecoxib, demonstrated allergic-type reactions to sulfonamides, experienced asthma, urticaria or allergic-type reactions after taking sulfonamides, aspirin (acetylsalicylic acid [ASA]), lactose or NSAIDs.
• The subject has been diagnosed as having or has been treated for gastrointestinal bleeding within 30 days before the screening visit.
• The subject has previously been admitted to this study.
• The subject has a likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (see Section 9 "Concomitant therapy").
• The subject has severe disease, likely to jeopardize the planned completion of the study
• The subject has abnormal baseline findings and or any other condition, which, in the investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
• The subject is not literate in French nor English or is unable according to the investigator to answer questions.
• The subject has received any investigational drug within 30 days prior to the screening visit.
• The subject has a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, transient ischemic attack, previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.
• The subject has congestive heart failure (Class II-IV).
• The subject is using aspirin, including low dose aspirin.
• The subject is using other antiplatelet agents (ticlopidine, clopidogrel, dipyridamole).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Pfizer Investigational Site

Kitchener, Ontario, Canada

Pfizer Investigational Site

London, Ontario, Canada

Pfizer Investigational Site

Newmarket, Ontario, Canada

Pfizer Investigational Site

Montreal, Quebec, Canada

Pfizer Investigational Site

Sainte-Foy, Quebec, Canada

Pfizer Investigational Site

Sainte-Foy, Quebec, Canada

Pfizer Investigational Site

Trois-Revieres, Quebec, Canada

Pfizer Investigational Site

St. John's, , Canada

Pfizer Investigational Site

Angers, , France

Pfizer Investigational Site

Antibes, , France

Pfizer Investigational Site

Arles, , France

Pfizer Investigational Site

Avignon, , France

Pfizer Investigational Site

Bagnols-sur-Cèze, , France

Pfizer Investigational Site

Beauvais, , France

Pfizer Investigational Site

Belfort, , France

Pfizer Investigational Site

Boulogne-sur-Mer, , France

Pfizer Investigational Site

Caen, , France

Pfizer Investigational Site

Cahors, , France

Pfizer Investigational Site

Cannes La Boca, , France

Pfizer Investigational Site

Castelnaudary, , France

Pfizer Investigational Site

Chateuauroux, , France

Pfizer Investigational Site

Chaumont, , France

Pfizer Investigational Site

Cherbourg, , France

Pfizer Investigational Site

Clamart, , France

Pfizer Investigational Site

Clichy, , France

Pfizer Investigational Site

Colmar, , France

Pfizer Investigational Site

Corbeil-Essonnes, , France

Pfizer Investigational Site

Cornebarrieu, , France

Pfizer Investigational Site

Courbevoie, , France

Pfizer Investigational Site

Créteil, , France

Pfizer Investigational Site

Dax, , France

Pfizer Investigational Site

Digne-les-Bains, , France

Pfizer Investigational Site

Dijon, , France

Pfizer Investigational Site

Épernay, , France

Pfizer Investigational Site

Firminy, , France

Pfizer Investigational Site

Fontainebleau, , France

Pfizer Investigational Site

Gardanne, , France

Pfizer Investigational Site

Gonesse, , France

Pfizer Investigational Site

Grenoble, , France

Pfizer Investigational Site

Issy-les-Moulineaux, , France

Pfizer Investigational Site

Ivry-sur-Seine, , France

Pfizer Investigational Site

Jonzac, , France

Pfizer Investigational Site

Joué-lès-Tours, , France

Pfizer Investigational Site

L'Aigle, , France

Pfizer Investigational Site

L'Union, , France

Pfizer Investigational Site

La Celle-Saint-Cloud, , France

Pfizer Investigational Site

La Rochelle, , France

Pfizer Investigational Site

Landivisiau, , France

Pfizer Investigational Site

Langon, , France

Pfizer Investigational Site

Laval, , France

Pfizer Investigational Site

Le Perreus Sur Marne, , France

Pfizer Investigational Site

Le Petit-Quevilly, , France

Pfizer Investigational Site

Les Angles, , France

Pfizer Investigational Site

Libourne, , France

Pfizer Investigational Site

Limoges, , France

Pfizer Investigational Site

Lisieux, , France

Pfizer Investigational Site

Lunel, , France

Pfizer Investigational Site

Lyon, , France

Pfizer Investigational Site

Lyon, , France

Pfizer Investigational Site

Lyon, , France

Pfizer Investigational Site

Lyon, , France

Pfizer Investigational Site

Maisons-Alfort, , France

Pfizer Investigational Site

Marseille, , France

Pfizer Investigational Site

Marseille, , France

Pfizer Investigational Site

Marseille, , France

Pfizer Investigational Site

Martigues, , France

Pfizer Investigational Site

Montgeron, , France

Pfizer Investigational Site

Montigny-le-Bretonneux, , France

Pfizer Investigational Site

Montluçon, , France

Pfizer Investigational Site

Montpellier, , France

Pfizer Investigational Site

Montpellier, , France

Pfizer Investigational Site

Montpellier, , France

Pfizer Investigational Site

Moulins, , France

Pfizer Investigational Site

Nancy, , France

Pfizer Investigational Site

Nantes, , France

Pfizer Investigational Site

Naucelle, , France

Pfizer Investigational Site

Neufchâteau, , France

Pfizer Investigational Site

Nevers, , France

Pfizer Investigational Site

Nice, , France

Pfizer Investigational Site

Nîmes, , France

Pfizer Investigational Site

Nogent-le-Rotrou, , France

Pfizer Investigational Site

Obernai, , France

Pfizer Investigational Site

Orléans, , France

Pfizer Investigational Site

Orléans, , France

Pfizer Investigational Site

Orly, , France

Pfizer Investigational Site

Ormesson-sur-Marne, , France

Pfizer Investigational Site

Orthez, , France

Pfizer Investigational Site

Paris, , France

Pfizer Investigational Site

Paris, , France

Pfizer Investigational Site

Paris, , France

Pfizer Investigational Site

Paris, , France

Pfizer Investigational Site

Paris, , France

Pfizer Investigational Site

Paris, , France

Pfizer Investigational Site

Poitiers, , France

Pfizer Investigational Site

Puteaux, , France

Pfizer Investigational Site

Quimper, , France

Pfizer Investigational Site

Reims, , France

Pfizer Investigational Site

Rennes, , France

Pfizer Investigational Site

Rennes, , France

Pfizer Investigational Site

Rodez, , France

Pfizer Investigational Site

Saint Afrique, , France

Pfizer Investigational Site

Saint Genevvieve Des Bois, , France

Pfizer Investigational Site

Saint Giron, , France

Pfizer Investigational Site

Saint Maxime, , France

Pfizer Investigational Site

Saint-Etienne, , France

Pfizer Investigational Site

Saint-Jacques-de-la-Lande, , France

Pfizer Investigational Site

Saint-Lô, , France

Pfizer Investigational Site

Saint-Pierre-de-Coutances, , France

Pfizer Investigational Site

Saint-Quentin, , France

Pfizer Investigational Site

Sartrouville, , France

Pfizer Investigational Site

Strasbourg, , France

Pfizer Investigational Site

Strasbourg, , France

Pfizer Investigational Site

Thionville, , France

Pfizer Investigational Site

Thonon-les-Bains, , France

Pfizer Investigational Site

Toulouse, , France

Pfizer Investigational Site

Toulouse, , France

Pfizer Investigational Site

Toulouse, , France

Pfizer Investigational Site

Toulouse, , France

Pfizer Investigational Site

Toulouse, , France

Pfizer Investigational Site

Tourcoing, , France

Pfizer Investigational Site

Tours, , France

Pfizer Investigational Site

Valence, , France

Pfizer Investigational Site

Vandœuvre-lès-Nancy, , France

Pfizer Investigational Site

Vence, , France

Pfizer Investigational Site

Versailles, , France

Pfizer Investigational Site

Villeneuve-sur-Lot, , France

Pfizer Investigational Site

Villeurbanne, , France

Pfizer Investigational Site

Vitré, , France

Pfizer Investigational Site

Vitrolles, , France

Countries

Canada; France

Related Links

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191068&StudyName=Effect+Of+Celecoxib+On+Hip+Osteoarthritis+%28OA%29+Progression

To obtain contact information for a study center near you, click here.

Other Identifiers

A3191068

Identifier Type: -

Identifier Source: org_study_id